Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Rhea-AI Summary
Arcutis (Nasdaq: ARQT) will report first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 PM ET.
A live webcast and presentation materials will be available in the Events section of the company website, with a replay posted on Arcutis investor site after the call.
Positive
- None.
Negative
- None.
News Market Reaction – ARQT
In the Apr 16 session, ARQT declined 1.59%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 22 | Earnings date set | Neutral | -1.7% | Scheduled Q4 and full-year 2025 results and investor conference appearances. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history for earnings-date announcements: the prior similar event saw a mild negative move of -1.69% despite being a routine scheduling update.
Recent Arcutis news has focused on pipeline progress, management updates, and investor communications. For earnings-related items specifically, the company previously announced its Q4 and FY 2025 results date on Jan 22, 2026, with a -1.69% next-day move. Today’s notice similarly sets timing for the Q1 2026 release and conference call at 4:30 p.m. ET, continuing a pattern of routine transparency around financial reporting and investor access.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30pm ET.
A live webcast of the call and related presentation materials will be available on the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis investor website following the conference call.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
